Comunicados de prensa - Ypsomed

mylife Loop improves health of pregnant women with type 1 diabetes and their babies

12/10/2023 - 07:00 Press Releases Ypsomed Group

Burgdorf – Pregnant women with type 1 diabetes and their babies benefit from treatment with a hybrid closed loop system based on the CamAPS FX algorithm. This is demonstrated by the AiDAPT clinical study, which clinical outcomes were published in the New England Journal of Medicine and the experience of the pregnant women in Diabetes Technology and Therapeutics, both on 5 October 2023. The algorithm of Ypsomed's mylife Loop, the CamAPS FX app is the only automated insulin delivery (AID) algorithm approved for pregnant women with type 1 diabetes.

Topics:

Innovation & Digital Health

Leer más... mylife Loop improves health of pregnant women with type 1 diabetes and their babies

Ypsomed enhances self-injection device platforms with integrated human factors services

05/10/2023 - 07:00 Press Releases Ypsomed Group

Burgdorf – Ypsomed announces new Human Factors (HF) services for its pharmaceutical partners to reinforce its position as a leading developer and manufacturer of self-injection solutions. By enhancing its device platform offering with integrated end-to-end HF services, Ypsomed is championing a comprehensive service approach to combination product development that de-risks regulatory approval and expedites time-to-market for its partners. To do so, Ypsomed has entered into a strategic partnership with Interface Analysis Associates LLC (IAA), a leading HF service provider with long-standing expertise in supporting the pharmaceutical industry along the full combination product development journey.

Topics:

Platforms & Operational Excellence

Leer más... Ypsomed enhances self-injection device platforms with integrated human factors services

Annual General Meeting of Ypsomed approves all proposals

29/06/2023 - 07:00 Press Releases Ypsomed Group

Burgdorf – The Annual General Meeting of Ypsomed Holding AG (SIX: YPSN) approved all proposals of the Board of Directors on 28 June 2023. More than 360 shareholders attended the event in Burgdorf. They confirmed all members of the Board of Directors in their office and re-elected Gilbert Achermann as Chairman of the Board of Directors.

Topics:

Management

Leer más... Annual General Meeting of Ypsomed approves all proposals

Ypsomed partners with S3 Connected Health to expand its digital health offering

07/06/2023 - 07:00 Press Releases Ypsomed Group

Burgdorf – Ypsomed (SIX: YPSN) will expand its offering of digital health solutions together with S3 Connected Health in the future. S3 Connected Health, headquartered in Dublin, Ireland is a specialist digital health partner for life science companies. The new offering will allow Ypsomed’s biopharma customers to quickly launch therapy-specific digital patient solutions. People with acute and chronic diseases can thus be supported fully in their therapy management and the outcome of their treatment can be enhanced.

Topics:

Innovation & Digital Health

Leer más... Ypsomed partners with S3 Connected Health to expand its digital health offering

Ypsomed expands production facility in Schwerin

09/05/2023 - 07:00 Press Releases Ypsomed Group

Burgdorf – Ypsomed (SIX: YPSN) is building a new production hall in Schwerin and creating 60 new jobs in the process. The company held the groundbreaking ceremony last Friday thus signaling the start of the construction for the 3300 square meters of additional production space, plus a further 1600 square meters for warehouse capacity and logistics. Digging work is scheduled to begin in June. The plant is expected to be operational following a construction phase of one year. The expansion will allow Ypsomed's site in Schwerin to produce more than 250 million infusion sets, pens and autoinjectors per year going forward.

Topics:

Access & Expansion

Leer más... Ypsomed expands production facility in Schwerin